Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy

  • Ogbomo H
  • Cinatl Jr J
  • Mody C
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Malignant gliomas (MGs) are deadly brain tumors with a median survival after resection, radiotherapy and chemotherapy of only 12 months. The natural immunosuppressive state of MG patients and the locally restricted growth of MGs render this neoplasm an excellent target for immunotherapy. Consequently, several failed attempts were made to treat MGs with immune cells. Recent preclinical experimental studies, however, demonstrate that natural killer (NK) cells can kill MGs and therefore hold promise in immunotherapy of MGs. This review describes the experimental and clinical evidence that support the potential of NK cells in therapy of MGs as well as the limitations to NK therapy. Finally, we propose strategies that could circumvent mitigating factors and enhance NK cell therapy for MG patients.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • Henry Ogbomo

  • Jindrich Cinatl Jr

  • Christopher H Mody

  • Peter A Forsyth

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free